Digene Infrastructure Scale-Up For DNA Pap Could Follow Failed Cytyc Merger

Digene may decide to expand its sales infrastructure for marketing the HPV DNA Pap test as a primary screen for cervical cancer if its pending merger with Cytyc does not occur